Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BlastMax is a private company focused on single-use, measured-dose cap and packaging technologies used to deliver ingredients at the point of use across beverage, nutraceutical, OTC, pharmaceutical, CBD, and related consumer health categories. The company markets patent-protected dosing formats such as Blast Caps, K-Cup dosing systems, nutritional straws, sachets, and micro-encapsulation-based delivery systems intended to keep active ingredients separate until consumption. Its business appears to center on licensing, private-label product development, formulation support, filling and sealing, and commercialization support rather than developing a traditional therapeutic drug pipeline. BlastMax positions its technology as improving stability, taste masking, time-release functionality, and shelf life for health-oriented formulations. Based on publicly available information, it is best characterized as a delivery-platform and product-enablement company with healthcare-adjacent applications rather than a clinical-stage biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BlastMax.